Its roles Owner Operator
Eli Lilly and Company (Lilly; NYSE: LLY) is a U.S.-based global pharmaceutical manufacturer that discovers, develops, and produces medicines for human health. Founded in 1876 and headquartered in Indianapolis, Indiana, the company’s portfolio spans small‑molecule and biologic therapies, with core focus areas including diabetes and metabolic diseases, immunology, oncology, and neuroscience.
Across the chemicals and life‑sciences value chain, Lilly operates extensive R&D and manufacturing networks for active pharmaceutical ingredients (APIs), biologics, and sterile injectable formulations, supported by global quality, regulatory, and supply‑chain systems. The company also develops drug‑delivery devices and collaborates with academic and industry partners to advance new therapeutic modalities.
Also known as Eli Lilly, Lilly USA, LLY, Eli Lilly USA, LLC, and Eli Lilly and Company.
chemXplore tracks 11 projects involving Lilly, of which 8 are active.
Besides these 8, the record holds 3 completed projects.
Closest to start-up first.
2 more active projects and the 3 that are completed, on hold or cancelled are in the record. See all 11 in chemXplore
1 active project carries no start-up date yet. The dates themselves, per project, are for subscribers.
The Fogelsville facility will make injectable medicines, including investigational retatrutide, and is expected to be operational by 2031.
ACR50 response reached 43.7% versus 15.7% with Taltz alone; exploratory results also showed metabolic and patient-reported improvements.
Phase 3 ATTAIN-OSA showed up to 44% AHI reduction, up to 55.9% lower hypoxic burden, ~11–11.5% weight loss, and improvements in blood pressure and inflammation; FDA submission planned by end of 2026.
Eligible patients can obtain Zepbound (tirzepatide) and Foundayo (orforglipron) via Hims & Hers telehealth with self-pay prices from $149/month for Foundayo and $299/month for Zepbound.
Phase 3 TRIUMPH trials showed retatrutide cut knee pain by up to 75.8% with some patients pain‑free; TOGETHER‑PsA found ixekizumab plus tirzepatide raised ACR50 to 43.7% at 52 weeks.
Q3 revenue rose 39% to $24.4B; 2026 revenue outlook raised to $91–$92B. Q3 included ~$900M of benefits and $4.2B IPR&D charges; multiple FDA approvals and positive late‑stage readouts reported.
At 80 weeks retatrutide lowered A1C by 2.2% and reduced weight ~20% (44–47 lbs) versus Ozempic 2 mg’s 1.8% A1C reduction and 9.4% (~21 lbs) weight loss.
Durable PFS and DOR not reached with immunotherapy combo; chemoimmunotherapy combo showed 62% ORR and 14.5‑month median DOR in first-line KRAS G12C NSCLC.
active all projects
What each is building and closing, and the pipelines and grids between them, on one map.